Showing 2231-2240 of 2657 results for "".
- Spark Therapeutics Announces Departure of CEO and Founder Jeff Marrazzo; COO Ron Philip Named as Successorhttps://modernod.com/news/spark-therapeutics-announces-departure-of-ceo-and-founder-jeff-marrazzo-coo-ron-philip-named-as-successor/2480664/Spark Therapeutics, a member of the Roche Group, announced that Ron Philip, Spark’s chief operating officer, will succeed co-founder Jeffrey D. Marrazzo as chief executive officer. Mr. Marrazzo, who co-founded the company in 2013, will step down on April 1. “When I thin
- Nicox Granted New Patent for NCX 4251 in Japanhttps://modernod.com/news/nicox-granted-new-patent-for-ncx-4251-in-japan/2480657/Nicox SA announced that the Japanese Patent Office has granted a new patent expiring in 2040 covering the company’s product candidate NCX 4251. Patent JP.7021301 covers ophthalmic suspensions comprising a specific form of fluticasone p
- Oyster Point Pharma Announces Tyrvaya Nasal Spray Now Covered by Express Scriptshttps://modernod.com/news/oyster-point-pharma-announces-tyrvaya-nasal-spray-now-covered-by-express-scripts/2480656/Oyster Point Pharma announced Tyrvaya Nasal Spray’s placement on the Express Scripts National Preferred, Basic, and High Performance Formularies, which collectively covers an estimated 26 million people, effective February 19, 2022. Tyrvaya is the first and only na
- EyeQue Launches MyReaderNumber App: Personalized Results for Reading and Computer Glasseshttps://modernod.com/news/eyeque-launches-myreadernumber-app-personalized-results-for-reading-and-computer-glasses-1/2480648/EyeQue introduced a first-of-its-kind smartphone app called MyReaderNumber that offers AR technology vision testing for presbyopia. EyeQue’s MyReaderNumber app is available for download for a one-time fee of $2.99 on the App Store (iOS only; available for iPhone X and newer) and c
- Waldo Announces the Acquisition of Placid0, Maker of Eye Assessment Apphttps://modernod.com/news/waldo-announces-the-acquisition-of-placid0/2480632/Waldo announces the acquisition of Placid0, maker of EASY, an eye assessment system mobile application. Financial terms of the deal were not disclosed. The acquisition is the next step in Waldo’s movement to make eye care an essential part of everyday life, with bo
- Glaukos Announces Executive Leadership Changeshttps://modernod.com/news/glaukos-announces-executive-leadership-changes/2480628/Glaukos announced several executive leadership changes to support the company’s future growth and strategic plans. The following executive changes will become effective on April 1, 2022: Joseph Gilliam will assume the new role of President and Chief Operating Officer.
- Tarsus Appoints José Trevejo, MD, PhD, Chief Medical Officerhttps://modernod.com/news/tarsus-appoints-jose-trevejo-md-phd-chief-medical-officer/2480613/Tarsus Pharmaceuticals announced the appointment of José Trevejo, MD, PhD, as Chief Medical Officer. Dr. Trevejo brings over 20 years of experience advancing the clinical development of novel therapeutics for serious diseases. Dr. Trevejo’s leadership will be highly valued
- FDA Approves First Generic of Restasishttps://modernod.com/news/fda-approves-first-generic-of-restasis/2480612/The FDA has approved the first generic of AbbVie's blockbuster dry eye drug Restasis (cyclosporine ophthalmic emulsion) 0.05%, which generated $1.23 billion in U.S. sales last year. The agency said it approved the generic Restasis single-use vials from Mylan Pharmaceuticals, wh
- Skye Bioscience Reports Potential Neuroprotective Benefit of SBI-100 In Preclinical Glaucoma Modelhttps://modernod.com/news/skye-bioscience-reports-potential-neuroprotective-benefit-of-sbi-100-in-preclinical-glaucoma-model/2480611/Skye Bioscience announced that in a preclinical study assessing the neuroprotective properties of its SBI-100 ophthalmic nanoemulsion, the treated group demonstrated a trend of retaining greater function of the eye’s retinal ganglion cells (RGCs) versus vehicle control. RGCs are cells
- Tarsus Completes Enrollment for the Pivotal Phase 3 Saturn-2 Trial of TP-03 to Treat Demodex Blepharitishttps://modernod.com/news/tarsus-completes-enrollment-for-the-pivotal-phase-3-saturn-2-trial-of-tp-03-to-treat-demodex-blepharitis/2480610/Tarsus Pharmaceuticals announced it has completed enrollment of Saturn-2, the company’s second pivotal phase 3 trial of TP-03 (lotilaner ophthalmic solution, 0.25%) for patients with Demodex blepharitis and executed a $175 million credit facility with Hercules Capital and Silicon